Xiaoran Zhang1, Aparana Rao1, Paola Sette1, Christopher Deibert1, Alexander Pomerantz1, Wi Jin Kim1, Gary Kohanbash1, Yigang Chang1, Yongseok Park1, Johnathan Engh1, Jaehyuk Choi1, Timothy Chan1, Hideho Okada1, Michael Lotze1, Paola Grandi1, Nduka Amankulor2. 1. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (X.Z., W.J.K.); Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (A.P., A.R., C.D., P.S., Y.C., J.E., P.G., N.A.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (G.K., H.O.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania (Y.P.); Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (J.C); Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (T.C); Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (M.L.); Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania (A.P.). 2. University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania (X.Z., W.J.K.); Department of Neurological Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (A.P., A.R., C.D., P.S., Y.C., J.E., P.G., N.A.); Department of Neurological Surgery, University of California San Francisco, San Francisco, California (G.K., H.O.); Department of Biostatistics, University of Pittsburgh, Pittsburgh, Pennsylvania (Y.P.); Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois (J.C); Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, New York (T.C); Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (M.L.); Department of Biological Sciences, Carnegie Mellon University, Pittsburgh, Pennsylvania (A.P.) amankulornm@upmc.edu.
Abstract
BACKGROUND: Diffuse gliomas are poorly immunogenic, fatal brain tumors. The basis for insufficient antitumor immunity in diffuse gliomas is unknown. Gain-of-function mutations in isocitrate dehydrogenases (IDH1 and IDH2) promote diffuse glioma formation through epigenetic reprogramming of a number of genes, including immune-related genes. Here, we identify epigenetic dysregulation of natural killer (NK) cell ligand genes as significant contributors to immune escape in glioma. METHODS: We analyzed the database of The Cancer Genome Atlas for immune gene expression patterns in IDH mutant or wild-type gliomas and identified differentially expressed immune genes. NKG2D ligand expression levels and NK cell-mediated lysis were measured in IDH mutant and wild-type patient-derived glioma stem cells and genetically engineered astrocytes. Finally, we assessed the impact of hypomethylating agent 5-aza-2'deoxycytodine (decitabine) as a potential NK cell sensitizing agent in IDH mutant cells. RESULTS: IDH mutant glioma stemlike cell lines exhibited significantly lower expression of NKG2D ligands compared with IDH wild-type cells. Consistent with these findings, IDH mutant glioma cells and astrocytes are resistant to NK cell-mediated lysis. Decitabine increases NKG2D ligand expression and restores NK-mediated lysis of IDH mutant cells in an NKG2D-dependent manner. CONCLUSIONS: IDH mutant glioma cells acquire resistance to NK cells through epigenetic silencing of NKG2D ligands ULBP1 and ULBP3. Decitabine-mediated hypomethylation restores ULBP1 and ULBP3 expression in IDH mutant glioma cells and may provide a clinically useful method to sensitize IDH mutant gliomas to NK cell-mediated immune surveillance in patients with IDH mutated diffuse gliomas.
BACKGROUND: Diffuse gliomas are poorly immunogenic, fatal brain tumors. The basis for insufficient antitumor immunity in diffuse gliomas is unknown. Gain-of-function mutations in isocitrate dehydrogenases (IDH1 and IDH2) promote diffuse glioma formation through epigenetic reprogramming of a number of genes, including immune-related genes. Here, we identify epigenetic dysregulation of natural killer (NK) cell ligand genes as significant contributors to immune escape in glioma. METHODS: We analyzed the database of The Cancer Genome Atlas for immune gene expression patterns in IDH mutant or wild-type gliomas and identified differentially expressed immune genes. NKG2D ligand expression levels and NK cell-mediated lysis were measured in IDH mutant and wild-type patient-derived glioma stem cells and genetically engineered astrocytes. Finally, we assessed the impact of hypomethylating agent 5-aza-2'deoxycytodine (decitabine) as a potential NK cell sensitizing agent in IDH mutant cells. RESULTS:IDH mutant glioma stemlike cell lines exhibited significantly lower expression of NKG2D ligands compared with IDH wild-type cells. Consistent with these findings, IDH mutant glioma cells and astrocytes are resistant to NK cell-mediated lysis. Decitabine increases NKG2D ligand expression and restores NK-mediated lysis of IDH mutant cells in an NKG2D-dependent manner. CONCLUSIONS:IDH mutant glioma cells acquire resistance to NK cells through epigenetic silencing of NKG2D ligands ULBP1 and ULBP3. Decitabine-mediated hypomethylation restores ULBP1 and ULBP3 expression in IDH mutant glioma cells and may provide a clinically useful method to sensitize IDH mutant gliomas to NK cell-mediated immune surveillance in patients with IDH mutated diffuse gliomas.
Authors: A Baragaño Raneros; V Martín-Palanco; A F Fernandez; R M Rodriguez; M F Fraga; C Lopez-Larrea; B Suarez-Alvarez Journal: Genes Immun Date: 2014-11-13 Impact factor: 2.676
Authors: Hideho Okada; Lisa H Butterfield; Ronald L Hamilton; Aki Hoji; Masashi Sakaki; Brian J Ahn; Gary Kohanbash; Jan Drappatz; Johnathan Engh; Nduka Amankulor; Mark O Lively; Michael D Chan; Andres M Salazar; Edward G Shaw; Douglas M Potter; Frank S Lieberman Journal: Clin Cancer Res Date: 2014-11-25 Impact factor: 12.531
Authors: Dan Rohle; Janeta Popovici-Muller; Nicolaos Palaskas; Sevin Turcan; Christian Grommes; Carl Campos; Jennifer Tsoi; Owen Clark; Barbara Oldrini; Evangelia Komisopoulou; Kaiko Kunii; Alicia Pedraza; Stefanie Schalm; Lee Silverman; Alexandra Miller; Fang Wang; Hua Yang; Yue Chen; Andrew Kernytsky; Marc K Rosenblum; Wei Liu; Scott A Biller; Shinsan M Su; Cameron W Brennan; Timothy A Chan; Thomas G Graeber; Katharine E Yen; Ingo K Mellinghoff Journal: Science Date: 2013-04-04 Impact factor: 47.728
Authors: Manuel A Friese; Michael Platten; Stefan Z Lutz; Ulrike Naumann; Steffen Aulwurm; Felix Bischof; Hans-Jörg Bühring; Johannes Dichgans; Hans-Georg Rammensee; Alexander Steinle; Michael Weller Journal: Cancer Res Date: 2003-12-15 Impact factor: 12.701
Authors: Bharathan Bhavya; C R Anand; U K Madhusoodanan; P Rajalakshmi; K Krishnakumar; H V Easwer; A N Deepti; Srinivas Gopala Journal: Cell Mol Neurobiol Date: 2019-09-04 Impact factor: 5.046
Authors: David A Sallman; Jason Brayer; Elizabeth M Sagatys; Caroline Lonez; Eytan Breman; Sophie Agaugué; Bikash Verma; David E Gilham; Frédéric F Lehmann; Marco L Davila Journal: Haematologica Date: 2018-04-27 Impact factor: 9.941
Authors: Lingjun Zhang; Mia D Sorensen; Bjarne W Kristensen; Guido Reifenberger; Thomas M McIntyre; Feng Lin Journal: Clin Cancer Res Date: 2018-07-13 Impact factor: 12.531
Authors: Tyler J Alban; Alvaro G Alvarado; Mia D Sorensen; Defne Bayik; Josephine Volovetz; Emily Serbinowski; Erin E Mulkearns-Hubert; Maksim Sinyuk; James S Hale; Giovana R Onzi; Mary McGraw; Pengjing Huang; Matthew M Grabowski; Connor A Wathen; Manmeet S Ahluwalia; Tomas Radivoyevitch; Harley I Kornblum; Bjarne W Kristensen; Michael A Vogelbaum; Justin D Lathia Journal: JCI Insight Date: 2018-11-02